Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II

Goldstein, EJC, Citron, DM, Gerding, DN et al. (5 more authors) (2020) Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. Clinical Infectious Diseases, 71 (4). ciz1151. pp. 1102-1105. ISSN 1058-4838

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in Clinical Infectious Diseases following peer review. The version of record Ellie J C Goldstein, Diane M Citron, Dale N Gerding, Mark H Wilcox, Lori Gabryelski, Alison Pedley, Zhen Zeng, Mary Beth Dorr, Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II, Clinical Infectious Diseases, , ciz1151, is available online at: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz1151/5689284 https://doi.org/10.1093/cid/ciz1151
Keywords: bezlotoxumab; Clostridioides difficile; recurrence; extension phase
Dates:
  • Published: 15 August 2020
  • Published (online): 28 December 2019
  • Accepted: 18 December 2019
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 21 Jan 2020 10:31
Last Modified: 28 Dec 2020 01:38
Status: Published
Publisher: Oxford University Press (OUP)
Identification Number: 10.1093/cid/ciz1151
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)